Bern (ots) - Der TCS Campingplatz in Sempach (LU) wird mit dem Camping.Info Award 2018 ausgezeichnet und ...
Genopole(R) and Three of its Campus Companies Will Attend the International BIO 2007 Trade Show
Evry, France (ots/PRNewswire) - The 2007 edition of the BIO (Biotechnology Industry Organization) trade show will be held in Boston (may 6-9). Genopole will attend this major event as part of a delegation coordinated by the Paris Il-de-France Regional Development Agency (ARD). Three innovative companies supported by Genopole(R) - Genewave, MATBiopharma and Vaxon Biotech - will equally be present at the show.
"The annual BIO show attracts the world's key biotech players. For a biocluster like Genopole, it's an event that we can't afford to miss", explains Pierre Tambourin, Genopole CEO. Since its foundation in 1998, Genopole has attended this event on a regular basis - enabling the cluster to achieve true international visibility."
"The BIO event enables us to meet our foreign counterparts and benefit from their experience but also allows us to showcase the novel approaches to biotech business support that we have implemented here at Genopole", adds Pierre Tambourin. In fact, our biopark stands out by combining a company incubator and a pre-seed fund (Genopole Day One), backed up by scientific and industrial infrastructure. Thanks to a broad array of financial, technological, scientific and real estate tools, a dense, rich fabric of companies has formed around Genopole."
Therapeutic innovation is the core concern of Genopole's stakeholders. The forthcoming establishment of a University Medical Center unit and the creation of a biomanufacturing facility at the heart of the campus will add the final building blocks to a biocluster which is already generating innovative medical techniques.
The Genopole portfolio now includes 62 enterprises, of which 35 have been founded or incubated on the campus. The Genopole biopark (with a strong biopharmaceutical theme) brings together drug discovery & development companies, technology providers and service companies. Twenty business have already commercialized products and/or services and 22 therapeutics are currently under development for a range of indications.
Three Genopole-mentored companies - Genewave, MATBiopharma and Vaxon Biotech (see over) - will attend the international BIO convention this year. "This event will offer our companies a great opportunity to showcase their products, skills and know-how. The business conventions, seminars and forums provide a host of occasions for meeting their future partners and customers", explains Véronique Dufey, Executive Director of Genopole Enterprise.
Three companies from the Genopole(R) portfolio will attend BIO 2007
Genewave develops, manufactures and sells a range of innovative biophotonic instruments and consumables for fl uorescence-based genomics and proteomics analysis techniques. This includes high sensitivity biochip substrates, compact biochip readers and systems with integrated fluidics as well as components for lab-on-a-chip devices. The Company also offers surface functionalization services.
Ultrasensitive systems, multiwell microarray readers, integrated microsystems, specifi c surface chemistries.
Immuno Targeting Company
MATBiopharma is engaged in the development of first-in-class antibody therapies for the treatment of cancer. The Company's most advanced product, Ferritarg(TM), is an antibody therapeutic for the treatment of Hodgkin's disease and will soon enter Phase I/II clinical trials. The MAT preclinical pipeline contains product candidates for acute myeloid leukemia, chronic lymphocytic leukemia, hepatocarcinoma, pancreatic cancer and metastatic melanoma. MAT is currently seeking partners in the US in order to accelerate downstream development of these compounds.
About Vaxon Biotech
New Horizons in Cancer Vaccine Therapy
Vaxon Biotech (founded in early 2004) is a product-driven biopharmaceutical company focusing on the discovery and development of innovative vaccines for the treatment of cancer. Vaxon Biotech is the first entrant to make vaccines with a new class of antigens: optimized cryptic peptides. These innovative vaccines show good tolerance and immunogenicity, both in animals and in Phase I cancer patients. The most advanced products are Vx-001 and Vx-006. Treatment with Vx-001 induced lengthy disease stabilization or a partial response in about 30% of patients. Vx-001 is due to enter a pivotal phase IIb clinical trial in hepatocellular cancer, together with a phase IIa study in non-small cell lung cancer. Vx-006, the second compound, should enter phase I/II clinical development in the prostate cancer field by Q4-2006.
Contact : Philippe Berthon, CEO
Press Contact :
Contact Genopole Enterprise :
Executive Director of Genopole Enterprise
ots Originaltext: Genopole
Im Internet recherchierbar: http://www.presseportal.ch
Press Contact : Genopole Communication, Caroline Villedieu,
+33-1-60-87-44-98, firstname.lastname@example.org; Contact Genopole
Enterprise : Executive Director of Genopole Enterprise, Véronique
Dufey, email@example.com, +33-1-60-87-84-46